Skip to contentG
Greenwich LifeSciences, Inc.
G
GLSIGreenwich LifeSciences, Inc. Released Mar 21, 2022, after the close
10-K filed Mar 21, 2022, 80 days after period end · 0001493152-22-007377
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.36M-$2.36MderivedN/M vs Q4 2020 No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Greenwich LifeSciences, Inc. · CIK 1799788 · Engraved from SEC EDGAR
N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,377,206N/M Operating Cash Flowderived-$2,264,320— ended Dec 31, 2021 · filed Mar 21, 2022 · 80 d after period end
+4.3% from the close of Mar 21, 2022 to the close of Mar 22, 2022, the first after the release.
after the close$21.47$22.39 Feb 11Mar 21Apr 29